Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics Limited has lodged an updated Appendix 3G with the ASX to notify the market of the issue, conversion or payment up of unquoted equity securities. The filing formally records changes to the company’s unquoted securities register, detailing adjustments relevant to investors tracking its capital structure.
The company stated that this Appendix 3G serves as an update to a prior announcement after an earlier Appendix 3B filing failed to link correctly on the ASX platform. By correcting the documentation and confirming the effective date as April 15, 2026, Percheron is seeking to ensure accurate disclosure and transparency for shareholders and market participants regarding its unquoted equity instruments.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australian-listed biotechnology company focused on developing therapeutic products in the life sciences sector. The company is traded on the ASX under the ticker PER and operates within the therapeutics industry, concentrating on research-driven healthcare solutions for patients and medical stakeholders.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.61M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.